Endo terminates inhaled fentanyl research pact
This article was originally published in Scrip
Endo Pharmaceuticalshas terminated its fentanyl research collaboration with Alexza Pharmaceuticalsfollowing a strategic review. In 2007 the firms agreed to develop an inhaled fentanyl product for the treatment of breakthrough pain using Alexza’s Staccato technology in North America. The product, Staccato fentanyl (AZ-003/EN-3284), has completed Phase I clinical studies, and its rights will be returned to Alexza.